Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5171303
Max Phase: Preclinical
Molecular Formula: C18H27BrN2O
Molecular Weight: 367.33
Associated Items:
ID: ALA5171303
Max Phase: Preclinical
Molecular Formula: C18H27BrN2O
Molecular Weight: 367.33
Associated Items:
Canonical SMILES: O[C@H]1CCCC[C@@H]1N1CCN(CCc2ccccc2Br)CC1
Standard InChI: InChI=1S/C18H27BrN2O/c19-16-6-2-1-5-15(16)9-10-20-11-13-21(14-12-20)17-7-3-4-8-18(17)22/h1-2,5-6,17-18,22H,3-4,7-14H2/t17-,18-/m0/s1
Standard InChI Key: BXWAJIMIRTUNLO-ROUUACIJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 367.33 | Molecular Weight (Monoisotopic): 366.1307 | AlogP: 2.91 | #Rotatable Bonds: 4 |
Polar Surface Area: 26.71 | Molecular Species: BASE | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 8.55 | CX LogP: 3.54 | CX LogD: 2.37 |
Aromatic Rings: 1 | Heavy Atoms: 22 | QED Weighted: 0.89 | Np Likeness Score: -0.53 |
1. Mishiro K, Wang M, Hirata S, Fuchigami T, Shiba K, Kinuya S, Ogawa K.. (2022) Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics., 13 (8.0): [PMID:36092143] [10.1039/d2md00099g] |
Source(1):